Navigation Links
Cowen Healthcare Royalty Partners Raises $1 Billion
Date:1/5/2012

STAMFORD, Conn., Jan. 5, 2012 /PRNewswire/ -- Cowen Healthcare Royalty Partners (Cowen Royalty), a global healthcare investment firm, today announced the closing of Cowen Healthcare Royalty Partners II, L.P. (CHRP II).  With approximately $1 billion in new capital commitments, Cowen Royalty will sustain its broad strategy of investing in traditional passive royalties, Synthetic royalties® and structured financings. Cowen Royalty exceeded the initial target for CHRP II by more than 75 percent.

"With a large amount of fresh capital and a healthy pipeline of financing opportunities and royalty asset sales, we believe we are well positioned to capitalize on this growing multi-billion dollar market opportunity," commented Clarke B. Futch, Founding Managing Director at Cowen Royalty.

Similar to its first fund, Cowen Royalty will target investments between $20MM-$100MM in the U.S., Europe and Asia.  The two main categories for capital investments include commercial stage biopharmaceutical and medical device companies in need of growth capital, and universities/inventors looking to monetize product interests.

"Increased demand for alternatives to traditional debt or equity by both companies and royalty owners will continue to drive this finance category going forward," further commented Cowen Royalty Founding Managing Director Todd C. Davis.

Since raising CHRP I in 2008, Cowen Royalty has made a total of 20 investments in 17 products including Lexiva® (GlaxoSmithKline), Cetrotide® (Merck Serono), Myozyme® (Genzyme, a Sanofi Company), Qutenza® (Astellas Pharma), Oracea® (Galderma) and KAMRA® inlay (AcuFocus). During the second half of 2011, Cowen Royalty closed eight (8) deals including product focused investments with Dyax Corp (DYAX), Stereotaxis, Inc. (STXS) and Zogenix (ZGNX), and royalty monetizations with several universities.  The Firm has continued to strengthen its team, adding experienced investment, financial, legal and operations professionals under the leadership of co-founders Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Futch.

In addition to existing Cowen Royalty limited partners, CHRP II LP's consist of a world-class list of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments.

Credit Suisse Securities (USA) LLC acted as exclusive financial advisor/placement agent and Goodwin Procter LLP as legal counsel.

About Cowen Healthcare Royalty Partners

Founded in 2007, Cowen Healthcare Royalty Partners is a global healthcare investment firm with over $1.5 billion of capital under management. The Firm specializes in structured financing solutions for the life sciences industry. For more information, visit www.cowenroyalty.com.

Media Contact:         

Kellie Walsh
914-315-6072
kwalsh@kwmcommunications.com

 


'/>"/>
SOURCE Cowen Healthcare Royalty Partners
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
3. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
4. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
5. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
6. Life Technologies to Present at the Cowen and Company 31st Annual Health Care Conference
7. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
8. Savient to Present at the Cowen and Company 30th Annual Health Care Conference
9. Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board
10. RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference
11. Amgen to Present at the Cowen and Company Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Spain , Dec. 8, 2016  Anaconda BioMed ... the development of the next generation neuro-thrombectomy system for ... appointment of Tudor G. Jovin, MD to join its ... serve as a strategic network of scientific and clinical ... the development of the ANCD BRAIN ® to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell ... RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture processes, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... This CAST literature ... for biotech crops. The authors focus on the economic effects in countries that are ... of new biotech crops and the resultant risk of low level presence (LLP) puts ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
Breaking Biology Technology:
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):